Evidence map›Paper›PMID 10933689›Full record

ArticleJournal of virology2000

Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1.

T Pierson, T L Hoffman, J Blankson, D Finzi, K Chadwick, J B Margolick, C Buck, J D Siliciano, R W Doms, R F Siliciano

3 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in Journal of virology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 69 papers.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00774683 completednot on this mapstarted 2008, after this paper: background citation

A Phase IV, Open-Label, Single-Sequence Pilot Study to Characterize the Pharmacokinetics of a 400mg Oral Dose of Raltegravir in the Cervicovaginal Fluids of HIV-Infected Women

TypeobservationalSponsorKristine Patterson, MDRan2008 to 2009Enrolled1ConditionsHIV, AIDSArmsRaltegravir (Isentress®)
NCT00961272 completednot on this mapstarted 2009, after this paper: background citation

An Open-Label, Pilot Study to Characterize the Pharmacokinetics of a 400mg Oral Dose of Raltegravir in the Cervicovaginal Fluids of HIV-Infected Pre-menopausal Women

TypeobservationalSponsorKristine Patterson, MDRan2009 to 2010Enrolled6ConditionsHIV Infections
NCT01325051 phase1completednot on this mapstarted 2011, after this paper: background citation

A Phase IV, Open-Label Study to Characterize the First-Dose and Multiple-Dose Pharmacokinetics of Raltegravir in the Gastrointestinal Tract of Healthy Male Volunteers

TypeinterventionalSponsorAngela Kashuba, PharmDRan2011 to 2011Enrolled15ConditionsHealthy VolunteerArmsRaltegravir
3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 144 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Different human resting memory CD4Science translational medicine · 2020
    Observational
  11. Review
  12. Measuring the Success of HIV-1 Cure Strategies.Frontiers in cellular and infection microbiology · 2020
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. CD4AIDS research and human retroviruses · 2018
    Review
  18. Review
  19. Review
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

T PiersonDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
T L Hoffman
J Blankson
D Finzi
K Chadwick
J B Margolick
C Buck
J D Siliciano
R W Doms
R F Siliciano
Johns Hopkins Medicine · USJohns Hopkins University · USUniversity of Pennsylvania · US

Funding

HIV entry and its inhibitionR01AI040880 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DOMS, ROBERT W. · 1997 to 2010
$4.2M
LATENT VIRAL RESERVOIRS IN HIV1 INFECTIONR01AI043222 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SILICIANO, ROBERT F · 1998 to 2013
$3.5M
NIAID NIH HHS AI40880NIAID NIH HHS AI43222NIAID NIH HHS R01 AI040880NIAID NIH HHS R01 AI043222
6 · The paper itself

Abstract

Latently infected resting CD4(+) T cells provide a long-term reservoir for human immunodeficiency virus type 1 (HIV-1) and are likely to represent the major barrier to virus eradication in patients on combination antiretroviral therapy. The mechanisms by which viruses enter the latent reservoir and the nature of the chemokine receptors involved have not been determined. To evaluate the phenotype of the virus in this compartment with respect to chemokine receptor utilization, full-length HIV-1 env genes were cloned from latently infected cells and assayed functionally. We demonstrate that the majority of the viruses in the latent reservoir utilize CCR5 during entry, although utilization of several other receptors, including CXCR4, was observed. No alternative coreceptors were shown to be involved in a systematic fashion. Although R5 viruses are present in the latent reservoir, CCR5 was not expressed at high levels on resting CD4(+) T cells. To understand the mechanism by which R5 viruses enter latent reservoir, the ability of an R5 virus, HIV-1 Ba-L, to infect highly purified resting CD4(+) T lymphocytes from uninfected donors was evaluated. Entry of Ba-L could be observed when virus was applied at a multiplicity approaching 1. However, infection was limited to a subset of cells expressing low levels of CCR5 and markers of immunologic memory. Naive cells could not be infected by an R5 virus even when challenged with a large inoculum. Direct cell fractionation studies showed that latent virus is present predominantly in resting memory cells but also at lower levels in resting naive cells. Taken together, these findings provide support for the hypothesis that the direct infection of naive T cells is not the major mechanism by which the latent infection of resting T cells is established.

Indexed as

Virus LatencyCD4-Positive T-LymphocytesGene Products, envHIV-1HIV InfectionsHumansReceptors, CCR5Receptors, CXCR4RNA, ViralGene Products, envReceptors, CCR5Receptors, CXCR4RNA, Viral

Identifiers

PMID10933689
PMCPMC112312
OpenAlexW2045452873

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.